Buprenorphine inhibits bradykinin-induced release of calcitonin gene-related peptide from rat trigeminal neurons via both μ-opioid and nociceptin/orphanin peptide receptors

European Journal of Pharmacology

Volumn 609, Issue 1-3, 2009, Pages 45-50

  Capuano, Alessandro ^a   De Corato, Alice ^a   Tringali, Giuseppe ^a   Currò, Diego ^a   Dello Russo, Cinzia ^a   Navarra, Pierluigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bradykinin; Buprenorphine; Calcitonin gene related peptide; NOP receptor; Rat trigeminal neuron

Indexed keywords

BRADYKININ; BUPRENORPHINE; CALCITONIN GENE RELATED PEPTIDE; INDOMETACIN; MU OPIATE RECEPTOR; NOCICEPTIN RECEPTOR; PROSTAGLANDIN E2; PROSTANOID;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; TRIGEMINAL NERVE;

ANALGESICS, OPIOID; ANIMALS; BRADYKININ; BUPRENORPHINE; CALCITONIN GENE-RELATED PEPTIDE; CELLS, CULTURED; NEURONS; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; TRIGEMINAL NERVE;

EID: 64549124296     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.03.013     Document Type: Article

References (47)

1. Attal N., Cruccu G., Haanpää M., Hansson P., Jensen T.S., Nurmikko T., Sampaio C., Sindrup S., and Wiffen P. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 13 (2006) 1153-1169
2. Berg K.A., Patwardhan A.M., Sanchez T.A., Silva Y.M., Hargreaves K.M., and Clarke W.P. Rapid modulation of micro-opioid receptor signaling in primary sensory neurons. J. Pharmacol. Exp. Ther. 321 (2007) 839-847
3. Bloms-Funke P., Gillen C., Schuettler A.J., and Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 21 (2000) 1141-1146
4. Calixto J.B., Cabrini D.A., Fereira J., and Campos M.M. Kinins in pain and inflammation. Pain 87 (2000) 1-5
5. Calixto J.B., Medeiros R., Fernandes E.S., Ferreira J., Cabrini D.A., and Campos M.M. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br. J. Pharmacol. 143 (2004) 803-818
6. 2 inhibits stimulated calcitonin gene-related peptide release from primary cultures of rat trigeminal ganglia neurones. Cephalalgia 27 (2007) 868-876
7. Cowan A. Update of the general pharmacology of buprenorphine. In: Lewis J., and Cowan A. (Eds). Buprenorphine: Combating Drug Abuse with a Unique Opioid (1995), Wiley, New York 31-47
8. Dionne R.A., Lepinski A.M., Gordon S.M., Jaber L., Brahim J.S., and Hargreaves K.M. Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation. Clin. Pharmacol. Ther. 70 (2001) 66-73
9. Dray A., and Perkins M. Bradykinin and inflammatory pain. Trends Neurosci. 16 (1993) 99-104
10. Dum J.E., and Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br. J. Pharmacol. 74 (1981) 627-633
11. Evers S., Afra J., Frese A., Goadsby P.J., Linde M., May A., and Sándor P.S. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur. J. Neurol. 13 (2006) 560-572
12. Fields H.L., Emson P.C., Leigh B.K., Gilbert R.F., and Iversen L.L. Multiple opiate receptor sites on primary afferent fibres. Nature 284 (1980) 351-353
13. Goadsby P.J., Edvinsson L., and Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and cat during activation of the trigeminal system. Ann. Neurol. 23 (1988) 193-196
14. Gupta A., Bodin L., Holmström B., and Berggren L. A systematic review of the peripheral analgesic effects of intraarticular morphine. Anesth. Analg. 93 (2001) 761-770
15. Hawkinson J.E., Acosta-Burruel M., and Espitia S.A. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur. J. Pharmacol. 389 (2000) 107-114
16. Hou M., Uddman R., Tajti J., and Edvinsson L. Nociceptin immunoreactivity and receptor mRNA in the human trigeminal ganglion. Brain Res. 964 (2003) 179-186
17. Huang P., Kehner G.B., Cowan A., and Liu-Chen L.Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 297 (2001) 688-695
18. 2 and CGRP release from rat trigeminal ganglion neurones in vitro. Cephalalgia 21 (2001) 355
19. Jenkins D.W., Sellers L.A., Feniuk W., and Humphrey P.P. Characterization of bradykinin-induced prostaglandin E2 release from cultured rat trigeminal ganglion neurones. Eur. J. Pharmacol. 469 (2003) 29-36
20. Koppert W., Ihmsen H., Korber N., Wehrfritz A., Sittl R., Schmelz M., and Schuttler J. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 118 (2005) 15-22
21. Li J.L., Ding Y.Q., Li J.S., Nomura S., Kaneko T., and Mizuno N. Immunocytochemical localization of μ-opioid receptor in primary afferent neurons containing substance P or calcitonin gene-related peptide. A light and electron microscope study in the rat. Brain Res. 794 (1998) 347-352
22. Lutfy K., Eitan S., Bryant C.D., Yang Y.C., Saliminejad N., Walwyn W., et al. Buprenorphine-induced antinociception is mediated by μ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J. Neurosci. 23 (2003) 10331-10337
23. Ma Q.P., Hill R., and Sirinathsinghji D. Basal expression of bradykinin B1 receptor in peripheral sensory gangla in the rat. Neuroreport 11 (2000) 4003-4005
24. Malin S.A., Davis B.M., and Molliver D.C. Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nat. Protoc. 2 (2007) 152-160
25. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
26. Minami M., Maekawa K., Yabuuchi K., and Satoh M. Double in situ hybridization study on coexistence of μ-, delta- and kappa-opioid receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root ganglia. Brain Res. Mol. Brain Res. 30 (1995) 203-210
27. Mogil J.S., and Pasternak G.W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol. Rev. 53 (2001) 381-415
28. Mollereau C., Parmentier M., Mailleux P., Butour J.L., and Moisand C. ORL-1, a novel member of the opioid receptor family: cloning, functional expression and localisation. FEBS Lett. 341 (1994) 33-38
29. Obara I., Przewlocki R., and Przewlocka B. Local peripheral effects of mu-opioid receptor agonists in neuropathic pain in rats. Neurosci. Lett. 360 (2004) 85-89
30. Patwardhan A.M., Berg K.A., Akopain A.N., Jeske N.A., Gamper N., Clarke W.P., and Hargreaves K.M. Bradykinin-induced functional competence and trafficking of the delta-opioid receptor in trigeminal nociceptors. J. Neurosci. 25 (2005) 8825-8832
31. Pertovaara A., and Wei H. Peripheral effects of morphine in neuropathic rats: role of sympathetic postganglionic nerve fibers. Eur. J. Pharmacol. 429 (2001) 139-145
32. Shannon H.E., and Lutz E.A. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats. Neuropharmacology 42 (2002) 253-261
33. Stein C., Millan M.J., Shippenberg T.S., Peter K., and Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J. Pharmacol. Exp. Ther. 248 (1989) 1269-1275
34. Stein C., Machelska H., Binder W., and Schafer M. Peripheral opioid analgesia. Curr. Opin. Pharmacol. 1 (2001) 62-65
35. Stein C., Schäfer M., and Machelska H. Attacking pain at its source: new perspectives on opioids. Nat. Med. 9 (2003) 1003-1008
36. Storer R.J., Akerman S., and Goadsby P.J. Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex. Br. J. Pharmacol. 138 (2003) 317-324
37. Tornabene, S.V., Deutsch, R., Davis, D.P., Chan, T.C., Vilke, G.M., in press. Evaluating the use and timing of opioids for the treatment of migraine headaches in the emergency department. J. Emerg. Med. doi:10.1016/j.jemermed.2007.07.068.
38. Tringali G., Pozzoli G., Vairano M., Mores N., Preziosi P., and Navarra P. Interleukin-18 displays effects opposite to those of interleukin-1 in the regulation of neuroendocrine axis. J. Neuroimmunol. 160 (2005) 61-67
39. Truong W., Cheng C., Xu Q.G., Li X.Q., and Zochodne D.W. Mu opioid receptors and analgesia at the site of a peripheral nerve injury. Ann. Neurol. 53 (2003) 366-375
40. 2 enhances Bradykinin-stimulated release of neuropeptides from rat sensory neurons in culture. J. Neurosci. 14 (1994) 4987-4997
41. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., and Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55 (1994) 569-580
42. Wang Y.Q., Zhu C.B., Cao X.D., and Wu G.C. Supraspinal hyperalgesia and spinal analgesia by [phe1psi(CH2-NH) Gly2]-nociceptin-(1-13)NH2 in rat. Eur. J. Pharmacol. 376 (1999) R1-R3
43. Whiteside G.T., Boulet J.M., and Walker K. The role of central and peripheral mu opioid receptors in inflammatory pain and edema: a study using morphine and DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid). J. Pharmacol. Exp. Ther. 314 (2005) 1234-1240
44. Wnendt S., Kruger T., Janocha E., Hildebrandt D., and Englberger W. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol. Pharmacol. 56 (1999) 334-338
45. Xie G.X., Meuser T., Pietruck C., Sharma M., and Palmer P.P. Presence of opioid receptor-like (ORL1) receptor mRNA splice variants in peripheral sensory and sympathetic neuronal ganglia. Life Sci. 64 (1999) 2029-2037
46. Yamamoto T., Shono K., and Tanabe S. Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test. J. Pharmacol. Exp. Ther. 318 (2006) 206-213
47. Zollner C., Shaqura M.A., Bopaiah C.P., Mousa S., Stein C., and Schafer M. Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol. Pharmacol. 64 (2003) 202-210